Abstract
Background: Rivaroxaban represents a selective direct inhibitor of activated coagulation factor X (FXa) having peroral bioavailability and prompt onset of action.
Objective: The absorbtion of rivaroxaban is quick, reaching maximum plasma concentration 2-4 hours following its administration. Peroral bioavailability is high (80-100 %) and pharmacokinetic variability is considered to be moderate (coefficient of variation 30-40 %). This review discusses the properties, drug interactions, pharmacokinetics and clinical indications of rivaroxaban. Method: Dosing regimen of rivaroxaban was derived from pharmacologic data of the development program aimed to gain strong antithrombotic drug and balance between efficacy and risk of bleeding in patients. Results of doseranging trials, pharmacokinetic models and randomised studies of phase III advocate the use of such schemes in everyday practice. Results: The drug has been manufactured to fulfill clinical requirements in a variety of indications in adults: prophylaxis of venous thromboembolism (VTE) following elective knee or hip replacement surgical intervention, therapy and secondary prophylaxis of VTE, prophylaxis of ischemic stroke and embolism in individuals diagnosed with nonvalvular atrial fibrillation (NVAF) with risky characteristics, and in Europe the prophylaxis of atherothrombotic episodes following an acute coronary syndrome in subjects with increased levels of cardiac biomarkers. Conclusion: Rivaroxaban may offer benefit in many clinical situations. In comparison with low molecular weight heparin and fondaparinux requiring subcutaneous way of administration, and with vitamin K antagonists (VKAs), which require regular monitoring of international normalized ratio, rivaroxaban is relatively easy to use. However, adjustments of dose are needed in individuals with impaired renal functions.Keywords: Anticoagulants, rivaroxaban, direct factor Xa inhibitor, venous thromboembolism, stroke, atrial fibrillation, pharmacodynamics.
Graphical Abstract
Current Drug Metabolism
Title:Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions
Volume: 18 Issue: 7
Author(s): Tomas Kvasnicka*, Ivana Malikova, Zuzana Zenahlikova, Karolína Kettnerova, Radka Brzezkova, Tomas Zima, Jan Ulrych, Jan Briza, Ivan Netuka and Jan Kvasnicka
Affiliation:
- Thrombotic Centre of Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, Karlovo Namesti 32, 121 11 Prague 2,Czech Republic
Keywords: Anticoagulants, rivaroxaban, direct factor Xa inhibitor, venous thromboembolism, stroke, atrial fibrillation, pharmacodynamics.
Abstract: Background: Rivaroxaban represents a selective direct inhibitor of activated coagulation factor X (FXa) having peroral bioavailability and prompt onset of action.
Objective: The absorbtion of rivaroxaban is quick, reaching maximum plasma concentration 2-4 hours following its administration. Peroral bioavailability is high (80-100 %) and pharmacokinetic variability is considered to be moderate (coefficient of variation 30-40 %). This review discusses the properties, drug interactions, pharmacokinetics and clinical indications of rivaroxaban. Method: Dosing regimen of rivaroxaban was derived from pharmacologic data of the development program aimed to gain strong antithrombotic drug and balance between efficacy and risk of bleeding in patients. Results of doseranging trials, pharmacokinetic models and randomised studies of phase III advocate the use of such schemes in everyday practice. Results: The drug has been manufactured to fulfill clinical requirements in a variety of indications in adults: prophylaxis of venous thromboembolism (VTE) following elective knee or hip replacement surgical intervention, therapy and secondary prophylaxis of VTE, prophylaxis of ischemic stroke and embolism in individuals diagnosed with nonvalvular atrial fibrillation (NVAF) with risky characteristics, and in Europe the prophylaxis of atherothrombotic episodes following an acute coronary syndrome in subjects with increased levels of cardiac biomarkers. Conclusion: Rivaroxaban may offer benefit in many clinical situations. In comparison with low molecular weight heparin and fondaparinux requiring subcutaneous way of administration, and with vitamin K antagonists (VKAs), which require regular monitoring of international normalized ratio, rivaroxaban is relatively easy to use. However, adjustments of dose are needed in individuals with impaired renal functions.Export Options
About this article
Cite this article as:
Kvasnicka Tomas*, Malikova Ivana, Zenahlikova Zuzana , Kettnerova Karolína , Brzezkova Radka , Zima Tomas , Ulrych Jan , Briza Jan , Netuka Ivan and Kvasnicka Jan , Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions, Current Drug Metabolism 2017; 18 (7) . https://dx.doi.org/10.2174/1389200218666170518165443
DOI https://dx.doi.org/10.2174/1389200218666170518165443 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Arterial Accelerated Aging in Dialysis Patients: The Clinical Impact of Vascular Calcification
Current Vascular Pharmacology Unfolding Cardiac Amyloidosis –From Pathophysiology to Cure
Current Medicinal Chemistry Biofilms: An Extra Hurdle for Effective Antimicrobial Therapy
Current Pharmaceutical Design Pharmacogenetics and Pharmagenomics, Trends in Normal and Pathological Aging Studies: Focus on p53
Current Pharmaceutical Design Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy
Current Pharmaceutical Design The Emerging Roles of Leptin and Ghrelin in Cardiovascular Physiology and Pathophysiology
Current Vascular Pharmacology The Status of Disease Registries in the United States: Reflections
Applied Clinical Research, Clinical Trials and Regulatory Affairs Meet the Editorial Board:
Central Nervous System Agents in Medicinal Chemistry Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells
Current Molecular Medicine Beyond the Cardiac Myofilament: Hypertrophic Cardiomyopathy- Associated Mutations in Genes that Encode Calcium-Handling Proteins
Current Molecular Medicine Curcumin: Not So Spicy After All
Mini-Reviews in Medicinal Chemistry Ribozyme- and Deoxyribozyme-Strategies for Medical Applications
Current Drug Targets Potential Role of Rho Kinase Inhibitors in Combating Diabetes-Related Complications Including Diabetic Neuropathy-A Review
Current Diabetes Reviews Thyroid Hormone-Induced Angiogenesis
Current Cardiology Reviews Growth Arrest Specific Gene (GAS) 6 Modulates Platelet Thrombus Formation and Vascular Wall Homeostasis and Represents an Attractive Drug Target
Current Pharmaceutical Design Low Osteopontin N-Terminal Fragment and Carotid Plaque Stability Associated with Statin or Antiplatelet Therapy
Current Vascular Pharmacology Regulation of Mitochondrial Function and its Impact in Metabolic Stress
Current Medicinal Chemistry Basal Septal Hypertrophy
Current Cardiology Reviews Macrovascular Complications of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Lysophospholipids: Synthesis and Biological Aspects
Current Organic Chemistry